Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Intravascular Hemolysis and the Pathophysiology of Sickle Cell Disease
source: The Journal of Clinical Investigation
year: 2017
authors: Kato GJ, Steinberg MH, Gladwin MT
summary/abstract:Hemolysis is a fundamental feature of sickle cell anemia that contributes to its pathophysiology and phenotypic variability. Decompartmentalized hemoglobin, arginase 1, asymmetric dimethylarginine, and adenine nucleotides are all products of hemolysis that promote vasomotor dysfunction, proliferative vasculopathy, and a multitude of clinical complications of pulmonary and systemic vasculopathy, including pulmonary hypertension, leg ulcers, priapism, chronic kidney disease, and large-artery ischemic stroke. Nitric oxide (NO) is inactivated by cell-free hemoglobin in a dioxygenation reaction that also oxidizes hemoglobin to methemoglobin, a non-oxygen-binding form of hemoglobin that readily loses heme. Circulating hemoglobin and heme represent erythrocytic danger-associated molecular pattern (eDAMP) molecules, which activate the innate immune system and endothelium to an inflammatory, proadhesive state that promotes sickle vaso-occlusion and acute lung injury in murine models of sickle cell disease. Intravascular hemolysis can impair NO bioavailability and cause oxidative stress, altering redox balance and amplifying physiological processes that govern blood flow, hemostasis, inflammation, and angiogenesis. These pathological responses promote regional vasoconstriction and subsequent blood vessel remodeling. Thus, intravascular hemolysis represents an intrinsic mechanism for human vascular disease that manifests clinical complications in sickle cell disease and other chronic hereditary or acquired hemolytic anemias.
organization: University of Pittsburgh School of Medicine, USA; Boston University School of Medicine, USADOI: 10.1172/JCI89741
read more full text
+myBinderRelated Content
-
Chip-based Models Mimic Organs to Advance Understanding of Sickle Cell DiseaseResearchers at Mississippi State Univers...
-
Beyond Hydroxyurea: New and Old Drugs in the Pipeline for Sickle Cell DiseaseDespite Food and Drug Administration (FD...
-
Identifying central sensitization in adults with sickle cell disease: Differences in clinical features and psychobeh...Central sensitization (CS) has been iden...
-
Small chips, big impact: MSU researcher studies cardiovascular, sickle cell diseaseA Mississippi State University researche...
-
Researchers ID key drivers of heart complications in sickle cell anemiaStudy opens path to earlier diagnosis, t...
-
Computer models provide new understanding of sickle cell diseaseComputer models developed by Brown Unive...
-
University researchers develop more complete model of sickle cellUniversity researchers have developed co...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.